"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin B 3
- B 3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Vitamin B3
- B3, Vitamin
- Nicotinamide
- Vitamin PP
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 13 | 15 |
| 2009 | 1 | 15 | 16 |
| 2010 | 1 | 11 | 12 |
| 2011 | 2 | 23 | 25 |
| 2012 | 2 | 15 | 17 |
| 2013 | 9 | 7 | 16 |
| 2014 | 8 | 13 | 21 |
| 2015 | 6 | 3 | 9 |
| 2016 | 4 | 5 | 9 |
| 2017 | 2 | 5 | 7 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12; 391(10):885-898.
-
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after =1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul; 38(7):1522-1533.
-
Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers. Respir Res. 2023 Nov 04; 24(1):265.
-
HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. J Neurosci. 2022 10 19; 42(42):7862-7874.
-
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2022 02 01; 24(2):229-244.
-
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 11 25; 138(21):2031-2041.
-
SIRT3 is required for liver regeneration but not for the beneficial effect of nicotinamide riboside. JCI Insight. 2021 04 08; 6(7).
-
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol. 2020 11; 22(11):1332-1345.
-
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326.
-
Cord Blood Expansion: A Clinical Advance. J Clin Oncol. 2019 02 10; 37(5):363-366.